NCT01937312View on ClinicalTrials.gov

Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue

PHASE4CompletedINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Ocular HypertensionOpen Angle Glaucoma
Interventions
DRUG

Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension

DRUG

Vehicle

Inactive ingredients used as a placebo comparator

DRUG

Prostaglandin analogue

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01937312 - Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue | Biotech Hunter | Biotech Hunter